Abstract P087 – Table 1. Summary of the number of PWH with reported use of DTG + 3TC by treatment history and baseline characteristic.
Treatment history			No. of PWH, n (N = 8034)
Treatment naive			788
Suppressed switch			6082
Treatment experienced with detectable viral load at baseline			58
Treatment experienced with unknown viremia			1106
	Studies identifying PWH with characteristic		Studies reporting effectiveness outcomes
Baseline characteristic	No. of cohorts	No. of PWH	No. of cohorts	No. of PWH
Previous virologic failure	7	1134	1	194
Evidence of baseline resistance	10	253	4	211
Evidence of HBV	6	166	1	35
Evidence of HCV	13	431	0	0
Treatment‐naive PWH with HIV‐1 RNA >500 000 copies/mL at baseline	1	18	1	18
Treatment‐experienced PWH with HIV‐1 RNA <50 copies/mL for <6 mo before switch	1	13	0	0

3TC, lamivudine; DTG, dolutegravir; HBV, hepatitis B virus; HCV, hepatitis C virus; PWH, people with HIV.